Investigation of new protective therapy of inner ear using a super anti-apoptotic protein, PTD-FNK
Investigation of new protective therapy of inner ear using a super anti-apoptotic protein, PTD-FNK
批准号:
16591731
负责人:
WATANABE Kenichi
金额:
$1.73万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2004
资助国家:
日本
项目状态:
已结题
起止时间:
2004 至 2005
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Introduction : Cisplatin (CDDP), a platinum-derived anti-cancer drug, induces apoptosis by DNA damage and is widely applied for the patients with head and neck cancer. On the other hand, CDDP has some side effects, such as ototoxicity, nephrotoxicity, and myelosuppression. The ototoxocity is one of the reasons to stop the chemotherapy. The super anti-apoptotic protein FNK, constructed from Bcl-x_L, exhibits the stronger activity to inhibit cell death. The fusion protein PTD-FNK of the HIV/Tat protein transduction domain (PTD) and FNK can enter into the cell body. PTD-FNK can be delivered to the brain to reduce ischemic injury, when i.p.injected into gerbils. Here, we investigated whether PTD-FNK protects inner ear from CDDP-induced hearing loss.Materials and Methods : PTD-FNK was s.c. injected 2 hours before the injection of CDDP. CDDP (17 mg/kg) was i.p.injected into the mice (C57/BL6). 7 days after the injection, ABR was recorded and animals were sacrificed. CDDP (1.5 mg/kg) also injected the tumor carrying mice and measured the tumor growth.Results : When CDDP (17 mg/kg) were i.p. injected into mice (C57/BL6), the survival rate was 57 %. On Day 7, all of the survived mice exhibited the elevation of ABR threshold. CDDP (1.5 mg/kg) inhibited an increase in the volume of tumor, when injected into tumor-carrying mice.Conclusions : PTD-FNK didn't affect the activity of CDDP to inhibit the tumor growth. PTD-FNK seems to penetrate the blood-inner ear barrier to protect inner ear from CDDP-induced ototoxicity. These results suggest that PTDFNK has great potential for clinical applications to prevent death of normal cells caused by side effects of anti-cancer drugs.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
細胞死抑制強化タンパク質FNKまたはそれをコードする核酸を含む抗癌治療の細胞毒性に基づく副作用の予防または治療剤
含有细胞死亡抑制增强蛋白FNK或编码它的核酸的抗癌治疗的细胞毒性副作用的预防剂或治疗剂
DOI:
--
发表时间:
2005
期刊:
影响因子:
--
作者:
[]
通讯作者:
細胞死抑制タンパク質FNKまたはそれをコードする核酸を含む抗癌治療の細胞毒性に基づく副作用の予防または治療剤
含有细胞死亡抑制蛋白FNK或编码它的核酸的抗癌治疗的细胞毒性副作用的预防剂或治疗剂
DOI:
--
发表时间:
2005
期刊:
影响因子:
--
作者:
[]
通讯作者:
Pathological and genetic study of inclusion body disease of Japanese brown cattle.
-
批准号:19K15994
-
项目类别:Grant-in-Aid for Early-Career Scientists
-
资助金额:$2.66万
-
财政年份:2019
-
负责人:WATANABE Kenichi
-
依托单位:
Non-destructive inspection of large structures using backscatter X-ray tomography
-
批准号:25630430
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.58万
-
财政年份:2013
-
负责人:WATANABE Kenichi
-
依托单位:
Fast electron density imaging with third generation Compton scattered X -ray CT
-
批准号:23760824
-
项目类别:Grant-in-Aid for Young Scientists (B)
-
资助金额:$2.91万
-
财政年份:2011
-
负责人:WATANABE Kenichi
-
依托单位:
Fatty acid metabolism of diabetic cardiomyopathy and failing heart
-
批准号:20590161
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.0万
-
财政年份:2008
-
负责人:WATANABE Kenichi
-
依托单位:
Abnormal genes and myocardial fatty acid metabolism in animal with hart dysfunction.
-
批准号:15390364
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$7.94万
-
财政年份:2003
-
负责人:WATANABE Kenichi
-
依托单位:
Structural Evolution of Enzymes from Antarctic Psychrotrophs and Molecular Mechanism for Their Higher Activities at Low Temperatures
-
批准号:13660096
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.3万
-
财政年份:2001
-
负责人:WATANABE Kenichi
-
依托单位:
Myocardial fatty acid metabolism and drug therapy in rats with heart failure.
-
批准号:13670750
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.62万
-
财政年份:2001
-
负责人:WATANABE Kenichi
-
依托单位:
海外基金